Compare Procter & Gamble Co (PG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Zimmer Biomet Holdings Inc — how do they compare? Procter & Gamble Co trades at $143.24 (market cap $331.31B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Procter & Gamble Co is far larger — about 18.4× Zimmer Biomet Holdings Inc's market cap, and Procter & Gamble Co pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| PG | ZBH | |
|---|---|---|
Market Cap | $331.31B | $18.05B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $104.26 |
52-Week Low | $138.10 | $79.58 |
Enterprise Value | $357.15B | $25.11B |
Dividend Yield | 3.05% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters and maintains robust profitability with a net margin of 18.44% and ROE of 30.13%. Recent news highlights its dividend reliability and supply chain enhancements, while analyst consensus leans bullish with a $162.50 price target.
PG offers steady growth and income appeal with a 69-year dividend growth streak, but premium valuation and soft demand outlook pose near-term risks. Upside hinges on execution amid economic pressures, with support at $143 and resistance at $146.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
